This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Pharmaceuticals UK Ltd.
Reference
McCarthy G, et al. Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK. Advances in Therapy : 6 Feb 2019. Available from: URL: http://doi.org/10.1007/s12325-019-0894-2
Rights and permissions
About this article
Cite this article
Intravitreal ranibizumab: QALY gains at acceptable cost in the UK. PharmacoEcon Outcomes News 822, 19 (2019). https://doi.org/10.1007/s40274-019-5671-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5671-6